Hengrui Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 5.751 billion yuan, an increase of 24.5% year-on-year
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Hengrui Pharma released its performance for the first three quarters of 2025, with the group achieving operating revenue of 23.188 billion yuan, an increase of 14.85% year-on-year; net profit attributable to shareholders of the listed company was 5.751 billion yuan, an increase of 24.5% year-on-year; basic earnings per share were 0.89 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments